manilatimes

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Paris and Tarrytown, NY, April 22, 2026. The US Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children aged two to 11 years with chronic spontaneous urticaria ...
manilatimes

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...
Finanznachrichten

Sanofi: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with CSU ...

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...
Pharmabiz

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous ...
PharmiWeb

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...
Pharmabiz

European Commission approves Sanofi & Regeneron’s Dupixent to treat young children with chronic spontaneous urticaria

European Commission approves Sanofi & Regeneron’s Dupixent to treat young children with chronic spontaneous urticaria: Paris Wednesday, April 15, 2026, 09:00 Hrs [IST] The Europ ...
Marietta Daily Journal

ASK THE DOCTORS: Lichen Sclerosus Can Occur in Many Places on the Body

Dear Doctors: I am a 64-year-old woman, and I was shocked when I was told I have lichen sclerosus. I have lesions on my wrist and arms, which cortisone cream has helped. I'm wondering if the ...
Mint

Simplex Infrastructures share price

Simplex Infrastructures Limited is an India-based civil engineering and construction contracting company. The Company is engaged in designing, engineering and construction for various projects such as ...
Seeking Alpha

LICN Lichen International Limited

Lichen International Limited, an investment holding company, provides financial and taxation, education support, and software and maintenance services in the People’s Republic of China. It offers ...